Barcha huquqlar himoyalangan.
0.00
0.00 (0.00%)
There is no data to display
MediWound Files Annual Report on Form 20-F YAVNE, Israel, March 5 , 202 6 -- MediWound Ltd. (Nasdaq: MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, t oday announced that it has filed its annual report on Form 20-F for the fiscal year ended December 31, 2025 with the U.S. Securities and Exchange Commission (the “SEC”) on March 5, 2026.
EscharEx ® Phase III VALUE trial advancing as planned Expanded NexoBrid ® manufacturing facility operational ; regulatory approvals expected in 2026 $17 million revenue in 2025 ; $54 million in cash at year-end; 2026–2028 revenue guidance reaffirmed Conference Call Today, March 5 , 202 6 , a t 8:30 a . m . Eastern Time YAVNE, Israel, March 05, 2026 (GLOBE NEWSWIRE) -- MediWound Ltd.
MediWound Provides Corporate Update and Financial Outlook Ahead of the J.P. Morgan Healthcare Conference
MediWound Reports New Clinical Data Demonstrating NexoBrid ® 's Effectiveness in Preventing Traumatic Tattoos After Abrasion and Blast Injuries